Drug Resistance (TB)

Rifampin Mono-resistance Remains Mysterious

Published in AIDS Weekly, August 24th, 1998

The primary cause of rifampin mono-resistance in tuberculosis patients remains something of a mystery, despite an investigation by researchers with the U.S. Centers for Disease Control and Prevention (CDC).

The CDC researchers found that prior rifabutin therapy as Mycobacterium avium complex (MAC)-prophylaxis could explain part, but not all, of the increase in rifampin mono-resistance among HIV positive tuberculosis patients.

"Although prior tuberculosis and rifabutin use were identified as risk factors for mono-rifampin resistance, these factors could not explain the majority of mono-rifampin resistant cases in this study," Renee Ridzon and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1998-08-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry